Cancer immunotherapy is experiencing a paradigm shift with the development of next-generation bispecific antibodies specifically designed for Non-Small Cell Lung Cancer (NSCLC) treatment. These sophisticated therapeutic agents represent a quantum leap from traditional monoclonal antibodies, offering dual-targeting capabilities that address the complex molecular landscape of lung...